Portal de investigação
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Guillo, L
- Abreu, M
- Panaccione, R
- Sandborn, WJ
- Azevedo, VF
- Gensler, L
- Moghaddam, B
- Ahuja, V
- Ali, SA
- Allez, M
- Ananthakrishnan, AN
- Bhattacharya, A
- Dubinsky, M
- Griffiths, A
- Hart, A
- Korelitz, B
- Kotze, PG
- Koutroubakis, IE
- Lakatos, PL
- Lindsay, JO
- Mantzaris, GJ
- Ng, SC
- O'Morain, C
- Panés, J
- Parigi, TM
- Ran, ZH
- Rogler, G
- Rubin, DT
- Sachar, DB
- Siegmund, B
- Steinwurz, F
- Tysk, C
- Vavricka, S
- Verstraete, SG
- Brezin, AP
- Haemel, AK
- Dignass, A
- Sands, BE
- Danese, S
- Peyrin-Biroulet, L
Unidades de investigação
Abstract
Extraintestinal manifestations occur frequently in patients with inflammatory bowel disease (IBD) and remain a diagnostic and therapeutic challenge. The aim of the Endpoints for Extraintestinal Manifestations in Inflammatory Bowel Disease Trials (EXTRA) initiative was to achieve international expert consensus on how to assess these manifestations in IBD trials. A systematic literature review was done to identify methods to diagnose extraintestinal manifestations in patients with IBD and measure treatment outcomes. A consensus meeting involving a panel of 41 attendees, including gastroenterologists and referral specialists, was held on March 31, 2021, as part of an International Organization for the Study of Inflammatory Bowel Diseases initiative. The panel agreed that a specialist's expertise is needed to confirm the diagnosis of extraintestinal manifestations before the inclusion of a patient in IBD trials, except for axial spondyloarthritis, for which typical symptoms and MRI can be sufficient. Easy to-measure endpoints were identified to assess the response of extraintestinal manifestations to treatment without needing specialist involvement. For uveitis, peripheral spondyloarthritis, and arthralgia, endpoint measurements need specialist expertise. The timing of endpoint measurements was discussed for individual extraintestinal manifestations. The EXTRA consensus proposes guidelines on how to thoroughly evaluate extraintestinal manifestations within IBD trials, and recommends that these guidelines are implemented in future trials to enable prospective assessment of these manifestations and comparison between studies.
Dados da publicação
- ISSN/ISSNe:
- 2468-1253, 2468-1253
- Tipo:
- Review
- Páginas:
- 254-261
- Link para outro recurso:
- www.scopus.com
LANCET GASTROENTEROLOGY & HEPATOLOGY Elsevier Ltd.
Citações Recebidas na Web of Science: 16
Citações Recebidas na Scopus: 22
Documentos
- Não há documentos
Filiações
Keywords
- CLASSIFICATION; PSORIASIS; CRITERIA; THERAPY
Financiamento
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Guillo L,Abreu M,Panaccione R,Sandborn WJ,Azevedo VF,Gensler L,Moghaddam B,Ahuja V,Ali SA,Allez M,Ananthakrishnan AN,Bhattacharya A,Dubinsky M,Griffiths A,Hart A,Korelitz B,Kotze PG,Koutroubakis IE,Lakatos PL,Lindsay JO,Magro F,Mantzaris GJ,Ng SC,O'Morain C,Panés J,Parigi TM,Ran ZH,Rogler G,Rubin DT,Sachar DB,Siegmund B,Steinwurz F,Tysk C,Vavricka S,Verstraete SG,Brezin AP,Haemel AK,Dignass A,Sands BE,Danese S,Peyrin L. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol. Hepatol. 2022. 7(3):p. 254-261. IF:35,700. (1).
